ArticleIranian journal of pharmaceutical research : IJPR2017
Protective Effect of
Article in Iranian journal of pharmaceutical research : IJPR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Novel Insight into the Cellular and Molecular Signalling Pathways on Cancer Preventing Effects ofJournal of cancer prevention · 2023Review
- Physiological Effects and Human Health Benefits ofPharmaceuticals (Basel, Switzerland) · 2022Review
- Cytotoxicity andHeliyon · 2022Article
- Hibiscus Acid fromMolecules (Basel, Switzerland) · 2022Article
- Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways.International journal of molecular sciences · 2021Article
- Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression.Frontiers in cell and developmental biology · 2020Article
- Salsolinol Attenuates Doxorubicin-Induced Chronic Heart Failure in Rats and Improves Mitochondrial Function in H9c2 Cardiomyocytes.Frontiers in pharmacology · 2019Article
- Potential Protective Effect ofBioMed research international · 2019Article
- Myocardial Protection from Ischemia-Reperfusion Damage by the Antioxidant Effect ofOxidative medicine and cellular longevity · 2019Article
- Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.Nutrients · 2018Article
- Preparation of β-CD-Ellagic Acid Microspheres and Their Effects on HepG2 Cell Proliferation.Molecules (Basel, Switzerland) · 2017Article
- Reversal of Doxorubicin-induced Cardiotoxicity by Using Phytotherapy: A Review.Journal of pharmacopuncture · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is an effective anticancer drug. But its clinical application is limited, because DOX induces apoptosis in cardiomyocytes and it leads to permanent degenerative cardiomyopathy and heart failure. Recent trainings showed that
Indexed as
Identifiers
28979325PMC5603880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.